1. Introduction

Digital Pathogen Simulation Restrictions refer to the legal, regulatory, ethical and technological limitations imposed on the creation, development, testing, distribution and use of computer-based models that simulate dangerous biological pathogens.

Digital pathogen simulations use technologies such as:

Artificial intelligence (AI) and machine learning.

Computational virology and bacteriology.

Genome and protein-structure modelling.

Digital twins of viruses and bacteria.

Computational modelling of pathogen mutations.

Virtual epidemiological and pandemic simulations.

Synthetic biology design software.

These technologies can contribute significantly to vaccine development, disease surveillance, drug discovery and pandemic preparedness. However, they can also create serious biosecurity risks if used to design, optimise or predict dangerous biological characteristics.

The central legal question is: To what extent can governments restrict digital biological simulations without unnecessarily interfering with scientific research, freedom of expression, academic freedom and technological innovation?

An important distinction is that a computer simulation is not automatically equivalent to creating or possessing a biological pathogen. Nevertheless, a simulation may become subject to regulatory restrictions when its purpose, capabilities, intended application or resulting information creates a substantial biological security risk.

There is currently no comprehensive, universally applicable legal regime specifically governing every form of digital pathogen simulation. Regulation instead emerges from biosecurity legislation, export controls, cybersecurity rules, scientific research governance, public-health legislation and international biological weapons restrictions.

2. Meaning and Scope of Digital Pathogen Simulation Restrictions

Digital pathogen simulation restrictions encompass legal controls over activities involving computational representations of potentially harmful biological agents.

The principal regulated activities include:

A. Simulation development

Restrictions may apply to computational systems designed to model dangerous biological agents, particularly where their capabilities could facilitate harmful biological applications.

B. Artificial intelligence-based pathogen modelling

AI systems can analyse biological datasets and generate predictions about biological properties. Regulatory concerns arise when such systems can facilitate dangerous applications.

C. Digital genome modelling

Computational representations of genetic information may raise concerns involving controlled biological sequences, sensitive genomic information and the potential misuse of scientific datasets.

D. Virtual pathogen experimentation

Computer-based experiments can generate information about biological behaviour without physically handling the pathogen. Such experiments may still require institutional risk assessment.

E. Distribution of simulation software

Developers, universities and technology companies may face restrictions when transferring controlled software, technical information or biological design capabilities across national borders.

F. Commercialisation

Companies offering pathogen-modelling platforms may face obligations involving customer verification, access controls, security assessments and responsible disclosure.

3. Objectives of Legal Restrictions

The main objectives are:

Prevention of biological weapons: Prevent computational research from facilitating biological weapons development.

Protection of public health: Reduce risks arising from misuse of pathogen-related technologies.

Responsible AI development: Ensure that AI-powered biological research operates within appropriate safety boundaries.

Protection of scientific information: Prevent unauthorised access to sensitive biological datasets.

Prevention of technological proliferation: Control transfers of sensitive software, technical information and biological design capabilities.

Research accountability: Establish responsibility for universities, laboratories, software developers and research institutions.

International security: Support international obligations against biological weapons.

4. International Legal Framework

A. Biological Weapons Convention, 1972

The Biological Weapons Convention (BWC) is the central international treaty prohibiting biological and toxin weapons.

It prohibits the development, production, stockpiling, acquisition and retention of biological agents and toxins of types and quantities that have no justification for peaceful purposes.

Relevance to digital pathogen simulations:

Although the Convention was drafted before modern AI and computational biology, its restrictions are relevant when digital modelling becomes part of activities intended to develop biological weapons.

The distinction is important:

Ordinary computational disease modelling is not automatically prohibited.

Simulations supporting legitimate vaccine and therapeutic research generally have peaceful purposes.

Computational activities knowingly assisting biological weapons development may raise serious treaty and domestic-law concerns.

The BWC does not establish a comprehensive licensing system for every computational biology programme.

B. United Nations Security Council Resolution 1540 (2004)

Resolution 1540 requires states to establish appropriate domestic controls to prevent non-state actors from acquiring weapons of mass destruction and related materials.

Its relevance includes national measures concerning sensitive biological materials, related technology and proliferation risks.

Digital pathogen simulation platforms may therefore become relevant to national proliferation-control policies, particularly where they facilitate access to controlled biological capabilities.

C. Australia Group Export-Control Arrangements

The Australia Group coordinates export controls concerning chemical and biological weapons-related materials and technologies.

Its significance for computational biology is that states can impose controls on relevant software, technical information and equipment where these fall within applicable export-control classifications.

These controls must be distinguished from a general prohibition on scientific computer modelling.

D. International Human Rights Law

Restrictions on digital pathogen simulations must also respect fundamental rights, including:

Freedom of expression.

Academic freedom.

Freedom of scientific research.

Privacy and data protection.

Freedom to receive and communicate information.

Article 19 of the International Covenant on Civil and Political Rights (ICCPR) permits certain restrictions on expression where prescribed by law and necessary for legitimate objectives such as national security and public health.

Consequently, governments should not prohibit scientific research merely because it concerns pathogens. Restrictions require a legally defensible and proportionate justification.

5. United States Legal Framework

The United States has developed important controls concerning biological research, pathogen-related software and technology transfers.

A. Biological Weapons Anti-Terrorism Act and 18 USC §175

Section 175 of Title 18 prohibits knowingly developing, producing, stockpiling, transferring, acquiring or possessing biological agents, toxins or delivery systems for use as weapons.

It also covers attempts, threats and conspiracies.

Application:

A digital simulation alone does not necessarily constitute development or possession of a biological agent under this provision.

However, computational work may become legally significant where it forms part of a knowing effort to develop or assist biological weapons.

B. Export Administration Regulations

The US Export Administration Regulations control specified dual-use technologies.

An important example is Export Control Classification Number (ECCN) 2D352, which covers certain software designed for controlled nucleic-acid assemblers and synthesizers and capable of designing and building functional genetic elements from digital sequence data.

This is a particularly important development because it demonstrates that biological security regulation can extend beyond physical biological materials to specialised software.

The control is not a blanket restriction on every genome-analysis or pathogen-simulation programme. Its application depends on the technical classification and relevant export-control rules.

RegInfo.gov+1

C. US Dual-Use Research Oversight

The 2024 US Government Policy for Oversight of Dual Use Research of Concern and Pathogens with Enhanced Pandemic Potential recognised the need for institutional oversight of potentially dangerous research.

It also encouraged institutional oversight of certain in-silico research capable of directly enabling the design of enhanced pandemic-potential pathogens or novel biological agents.

The 2026 policy developments should also be considered when assessing the current US framework.

Office of Science Policy+1

6. Australian Legal Framework

Australia provides an important example of regulating biological technology through a combination of biosecurity, gene technology and research governance legislation.

A. Biosecurity Act 2015 (Cth)

The Biosecurity Act 2015 establishes a framework for managing biosecurity risks.

Its primary focus includes the entry, movement and management of biological risks and relevant goods.

A purely digital simulation does not automatically become a regulated biological specimen or biological import merely because it models a pathogen.

However, associated physical materials, regulated organisms, samples and other activities may fall within the legislation.

B. Gene Technology Act 2000 (Cth)

The Gene Technology Act 2000 regulates dealings involving genetically modified organisms.

Its framework includes:

Risk assessment.

Regulatory authorisation.

Institutional biosafety oversight.

Monitoring and enforcement.

Regulation of relevant dealings involving GMOs.

A simulation that only models a hypothetical genetic sequence is not automatically a dealing with a GMO. Actual laboratory activities and subsequent biological applications must be assessed separately.

The legislation's principal objective is to protect human health and the environment by identifying and managing risks arising from gene technology.

Office of the Gene Technology Regulator+2

C. Environmental Protection and Biodiversity Conservation Act 1999

The EPBC Act may become relevant when activities involving genetically modified organisms or biological research create potential impacts on protected environmental matters.

It should not be interpreted as a general licensing statute for ordinary computer simulations.

D. Institutional Research Governance

Australian universities and research organisations should consider:

Institutional biosafety committee assessments.

Research ethics requirements where applicable.

Laboratory access controls.

Cybersecurity safeguards.

Data access and retention policies.

Risk assessment for dual-use research.

The legal distinction between digital modelling and physical biological experimentation remains essential.

7. Indian Legal Framework

India does not currently have a standalone statute specifically regulating digital pathogen simulations. However, several existing laws may become relevant depending on the nature and purpose of the activity.

A. Weapons of Mass Destruction and their Delivery Systems (Prohibition of Unlawful Activities) Act, 2005

This is one of the most important Indian statutes for biological weapons-related activities.

Section 4 defines biological weapons by reference to microbial or other biological agents and toxins of types and quantities that have no justification for prophylactic, protective or other peaceful purposes.

The legislation addresses prohibited activities involving biological weapons and associated technologies.

Relevance to digital pathogen simulations:

Simulation software intended to support biological weapons development may raise legal concerns.

Knowingly assisting prohibited biological weapons activities may attract liability.

Export of relevant technology may be restricted.

Corporate responsibility may arise where statutory requirements for offences by companies are satisfied.

However, a digital simulation without the development, acquisition or transfer of a biological weapon is not automatically an offence under the Act.

B. Environment (Protection) Act, 1986

The Environment (Protection) Act, 1986 provides the foundation for regulating activities involving hazardous microorganisms and genetically engineered organisms.

The 1989 Rules regulate the manufacture, use, import, export and storage of hazardous microorganisms, genetically engineered organisms and cells.

These provisions become relevant when computational research moves into physical biological experimentation.

C. Information Technology Act, 2000

The IT Act may apply where pathogen simulation platforms involve:

Unauthorised access to computer systems.

Data theft.

Cyberattacks against biological research infrastructure.

Unlawful access to confidential research databases.

Certain forms of computer-related fraud or misuse.

Section 43 and Section 66 are particularly relevant to unauthorised computer access and specified computer-related offences.

However, these provisions should not be interpreted as a general prohibition on developing pathogen simulation software.

D. Digital Personal Data Protection Act, 2023

The DPDP Act may become relevant when pathogen simulations involve identifiable personal data, including certain health-related information.

Organisations processing personal data must consider applicable obligations concerning lawful processing, security safeguards and individual rights.

The applicability of the Act depends on its operative provisions and the nature of the information being processed.

E. SCOMET Export Controls

India's Special Chemicals, Organisms, Materials, Equipment and Technologies (SCOMET) framework regulates specified sensitive exports.

Section 14C of the Foreign Trade (Development and Regulation) Act, 1992 is particularly relevant to exports intended for use in the design or manufacture of weapons of mass destruction.

This is significant for digital pathogen simulation platforms where software or technical information may be connected with controlled biological technologies.

IndiaCode+2

8. Important Case Laws and Their Legal Significance

An important qualification is necessary: there is no established body of reported judicial decisions directly deciding the legality of AI-based digital pathogen simulations. The following judgments provide analogous legal principles concerning dangerous technical information, scientific expression, export restrictions, national security and proportionality.

Case 1. United States v. Progressive, Inc. (1979)

Citation: 467 F. Supp. 990 (W.D. Wis. 1979).

Facts:

The magazine The Progressive intended to publish an article containing information about the design of a hydrogen bomb.

The US Government sought an injunction to prevent publication, arguing that disclosure could threaten national security.

Legal issue:

Whether the government could prevent publication of technically sensitive information on national-security grounds.

Decision:

The district court initially granted a temporary restraining order and subsequently a preliminary injunction.

The litigation ended after the information became publicly available elsewhere, and the injunction was dissolved.

Relevance to digital pathogen simulations:

This case provides an analogy for government restrictions on publishing dangerous technical information.

For example, authorities might seek restrictions on the publication of computational research that could materially facilitate biological weapons development.

However, the case does not establish that all dangerous scientific information can automatically be suppressed.

Case 2. Bernstein v. United States Department of State (1996)

Citation: 922 F. Supp. 1426 (N.D. Cal. 1996).

Facts:

Daniel Bernstein, a mathematician, challenged US export-control restrictions affecting the publication and distribution of cryptographic computer source code.

Legal issue:

Whether computer source code and its publication could receive constitutional protection as expression.

Decision:

The district court recognised that cryptographic source code was protected by the First Amendment.

Relevance:

Digital pathogen simulation software may have two characteristics:

It communicates scientific and computational information.

It performs technical functions that may have security implications.

Therefore, a government restriction on distributing simulation software may raise constitutional questions involving freedom of expression and scientific communication.

Case 3. Junger v. Daley (2000)

Citation: 209 F.3d 481 (6th Cir. 2000).

Facts:

Professor Peter Junger challenged restrictions affecting the publication of encryption source code.

Legal issue:

Whether computer source code is protected expression despite its functional capabilities.

Decision:

The Sixth Circuit held that computer source code is protected by the First Amendment because it communicates information and ideas among programmers.

It nevertheless recognised that the functional characteristics of software are relevant when assessing permissible government regulation.

Relevance:

This is particularly significant for AI-based pathogen modelling.

A scientific simulation can simultaneously be:

An academic research product.

A form of scientific communication.

A functional computational tool.

A potential instrument of biological misuse.

Consequently, regulators should distinguish educational publications from software capabilities that materially facilitate prohibited activities.

Justia Law+2

Case 4. Anuradha Bhasin v. Union of India (2020)

Citation: (2020) 3 SCC 637.

Court: Supreme Court of India.

Facts:

The case concerned restrictions on internet and communication services in Jammu and Kashmir.

Legal issue:

Whether restrictions affecting internet access and freedom of expression could be imposed without satisfying constitutional requirements.

Decision:

The Supreme Court recognised that freedom of speech and expression through the internet is constitutionally protected under Article 19(1)(a).

It emphasised proportionality, publication of restriction orders and judicial review.

Relevance:

Suppose the Indian Government prohibits access to an entire digital pathogen simulation platform because some of its capabilities may create biosecurity risks.

Such restrictions should be assessed against:

The legitimacy of the security objective.

The evidence supporting the restriction.

The necessity of the measure.

The availability of less restrictive alternatives.

The duration and scope of the restriction.

A targeted access restriction may be more defensible than an indefinite prohibition on all scientific simulations.

Indian Kanoon+1

Case 5. Modern Dental College and Research Centre v. State of Madhya Pradesh (2016)

Citation: (2016) 7 SCC 353.

Court: Supreme Court of India.

Legal principle:

The Supreme Court explained the doctrine of proportionality in reviewing restrictions on constitutional rights.

The relevant considerations include:

Whether the measure pursues a proper purpose.

Whether it is rationally connected to that purpose.

Whether a less restrictive alternative is available.

Whether the benefits justify the infringement of rights.

Relevance:

A regulatory authority restricting digital pathogen simulation should establish why the restriction is necessary.

For instance, requiring additional security reviews for a particularly sensitive research platform may be preferable to prohibiting all computational biological research.

Case 6. Justice K.S. Puttaswamy (Retd.) v. Union of India (2017)

Citation: (2017) 10 SCC 1.

Court: Supreme Court of India.

Legal issue:

Whether privacy is a fundamental right under the Constitution of India.

Decision:

The Supreme Court unanimously recognised privacy as a fundamental right under Article 21 and other constitutional guarantees.

Relevance:

Digital pathogen simulation may involve large datasets containing:

Patient information.

Genetic information.

Epidemiological records.

Clinical research information.

Identifiable health records.

Unauthorised disclosure or excessive processing of such information can create privacy and constitutional concerns.

The judgment provides an important foundation for balancing public-health research with individual privacy.

These Indian judgments establish relevant constitutional principles, although none directly decides the legality of digital pathogen simulations.

9. Major Legal Issues in Digital Pathogen Simulation

A. Freedom of Scientific Research versus National Security

One of the most difficult questions is whether scientific researchers can freely develop and publish computational pathogen models.

Universities may argue that computational modelling is essential for scientific advancement. Governments may argue that unrestricted dissemination could create biological security threats.

The legal solution requires balancing scientific freedom against demonstrable security risks.

B. Liability for Dangerous AI-generated Simulations

A difficult question arises when an AI system generates a dangerous biological simulation without the developer expressly intending that outcome.

Potentially responsible parties may include:

AI developers.

Software companies.

Research institutions.

Principal investigators.

Organisations distributing sensitive computational tools.

Users intentionally misusing the technology.

Liability should depend on applicable statutory duties, knowledge, foreseeability, causation and the person's actual contribution to the prohibited conduct.

Mere creation of an AI system should not automatically establish criminal responsibility for every subsequent misuse.

C. Cross-Border Distribution of Simulation Software

Digital pathogen simulations can be transferred through cloud platforms, software repositories and international research collaborations.

This creates jurisdictional conflicts.

For example, software may be developed in India, hosted in the United States and accessed by researchers in Australia.

Questions arise concerning:

Which country's export-control rules apply?

Whether the software is a controlled technology.

Whether foreign researchers require authorisation.

Whether the platform must verify users.

Whether the transfer creates biological weapons proliferation risks.

D. Academic Publication Restrictions

Scientific journals and universities may face difficult decisions when reviewing research that contains potentially dangerous computational information.

Possible regulatory responses include:

Independent biosecurity review.

Restricted access to sensitive research.

Publication of non-sensitive findings.

Institutional approval requirements.

Responsible disclosure procedures.

However, censorship should not be imposed merely because research concerns infectious diseases.

E. Commercial AI Platform Accountability

Commercial companies developing biological modelling systems may need internal governance arrangements.

These may include:

Risk classification.

User verification.

Security audits.

Access management.

Incident reporting.

Research documentation.

Independent technical assessments.

The appropriate legal requirements depend on the platform's actual capabilities and applicable national legislation.

10. Regulatory Challenges

11. Proposed Governance and Accountability Framework

A balanced regulatory system should incorporate the following principles.

1. Risk-based classification

Digital pathogen simulation systems should be classified according to their actual technical capabilities, intended use and reasonably foreseeable risks.

2. Research authorisation

Particularly sensitive research should undergo appropriate institutional and regulatory review.

3. Controlled access

High-risk computational capabilities may require proportionate access restrictions and security verification.

4. Transparency

Institutions should maintain records of relevant research approvals, risk assessments and security incidents.

5. Independent auditing

Independent experts should periodically evaluate whether security measures remain effective.

6. International cooperation

Countries should cooperate on common standards for dual-use computational biology, technology transfers and research governance.

7. Protection of legitimate research

Regulation should preserve ordinary disease modelling, vaccine research, educational simulations and legitimate scientific communication.

8. Accountability for misuse

Intentional assistance in prohibited biological weapons activities should attract appropriate legal consequences under applicable domestic and international law.

12. Important Distinction: Simulation versus Biological Experimentation

The legal classification must be based on the actual activity rather than simply the word pathogen.

13. Future Development of Digital Pathogen Simulation Law

Future regulation is likely to focus on five emerging areas.

First, AI biosecurity regulation: Governments may introduce specific standards for AI systems capable of generating high-risk biological designs.

Second, computational research licensing: Sensitive simulation capabilities may become subject to additional institutional or regulatory approval.

Third, digital biological export controls: Export-control systems may increasingly address software, datasets and computational capabilities.

Fourth, international legal harmonisation: Countries may develop common standards for digital biological research and dual-use technology transfers.

Fifth, algorithmic accountability: Courts and regulators may increasingly examine responsibility when AI-generated scientific outputs contribute to foreseeable biological risks.

The US regulatory debate already recognises the importance of computational biology. The Congressional Research Service has discussed the relationship between AI, biological design and biosecurity oversight.

Every CRS Report+1

14. Conclusion

Digital Pathogen Simulation Restrictions represent an emerging area of biotechnology law, cybersecurity law and international biosecurity governance.

The central legal challenge is not simply whether digital simulations should be prohibited. It is determining when computational biological research creates sufficiently serious risks to justify government intervention.

The Biological Weapons Convention, India's WMD Act 2005, the US Biological Weapons Anti-Terrorism Act, export-control legislation and Australia's Biosecurity Act 2015 provide important foundations for regulating relevant activities.

The judicial decisions in Bernstein, Junger, Progressive, Anuradha Bhasin, Modern Dental College and Puttaswamy provide useful principles for balancing national security, scientific expression, proportionality and privacy.

The most appropriate legal approach is risk-based regulation rather than blanket prohibition. Legitimate scientific research should remain protected, while computational capabilities that knowingly facilitate biological weapons development should be subject to effective legal controls.

The future of this field will depend on establishing a regulatory balance between scientific innovation, technological accountability, public health and international security.

15. Important Legal References

Key cases for academic citation:

United States v. Progressive, Inc., 467 F. Supp. 990 (1979).

Bernstein v. United States Department of State, 922 F. Supp. 1426 (1996).

Junger v. Daley, 209 F.3d 481 (2000).

Anuradha Bhasin v. Union of India, (2020) 3 SCC 637.

Modern Dental College v. State of Madhya Pradesh, (2016) 7 SCC 353.

Justice K.S. Puttaswamy v. Union of India, (2017) 10 SCC 1.

Academic research qualification: These are analogous authorities, not direct precedents establishing a specific offence or licensing requirement for digital pathogen simulations. The distinction is important when using this topic in a legal dissertation or research paper.